Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FRA:0NFA) is Built to Make THE BIGGEST EVER Breakthroughs in Natural Medicine and Virtual Care
Humanity is in a very dark place right now.
Before the year began, we were already dealing with all types of anxiety-inducing issues, from war to famines to diseases and climate change.
But then 2020 happened, and now we’re hit with a barrage of a mentally crippling separation from all that we would turn to in times of crisis: our neighbors, our family, our churches, our schools, our friends, etc.
The global health crisis has created separation, which in turn is creating large amounts of despair.
It has led to an increase in Anxiety, Stress, Addiction, Depression, and Suicides.1
Worldwide, the World Health Organization (WHO) estimates 1 in 4 people on the planet will be affected by mental or neurological disorders at some point of their lives—with over 450 Million people suffering from mental illness RIGHT NOW.2
Most people just don’t have the resources available or are unresponsive to current treatments on the market.
And sadly, for those that do, most of the mental health meds being peddled by Big Pharma actually cause more harm than good.
What the street’s been searching for is a company that has the types of material advantages that will make it a winner in this blossoming industry.
We’ve discovered a company that has a world-class management and research team behind it, and an undeniably incredible market advantage at the research and API level.
But also, a company with a state-of-the-art telemedicine platform to help connect therapists and patients, during a time when people are being kept apart.
This company is conducting research that could completely revolutionize the mental health field as we know it.
Best of all, this company is undervalued compared to its peers at USD$0.36 per share! The company has closed back-to-back seed rounds of financing,3 including a more than $1.5 million private placement led by Canaccord Genuity,4 and raised more than $4.5 million for the build-out of its state-of-the-art mycology lab and expansion of operations.
Let’s get into why Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) is the PREMIER life sciences company at the forefront of researching, developing, and producing psychedelic medicine and a leader in the telehealth industry.
10 Reasons Why Mydecine Innovations Group, Inc., (“Mydecine”) (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) Could Potentially Be the Best Biotech Play of the Year
- Robust clinical trial pipeline, launched world’s first trials for psilocybin against PTSD
- Advanced digital telehealth platform to make mental healthcare more affordable and convenient
- Introducing new lines of consumer-based fungtional™ mushroom vitality products
- World-renowned Medical & Scientific Advisory Board
- Deep intellectual property portfolio and patent filing timeline
- Unparalleled global relationships with military and veteran organizations
- State-of-the-art mycology laboratory for genetic R&D
- Robust Health Canada Schedule 1 Drugs and Substances Dealer’s License
- First in the world with full capabilities to legally cultivate, extract, conduct R&D, and produce, sell, and distribute certified cGMP pharmaceutical grade psilocybin globally
- Built-in USA distribution to the largest retail chains in North America, such as Whole Foods, Kroger, Costco, and HEB
Life sciences company Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) is dedicated to developing and producing adaptive pathway medicine, natural health products, and virtual healthcare solutions.
By leveraging strategic partnerships with scientific, medical, military, and clinical organizations, Mydecine is poised to make an incredible impact on what they have dubbed the “fungtional” mushroom market.
It’s led by an incredible management and advisory team, which includes multiple Nobel prize nominations, expertise tied to the monumental North American launch of Red Bull,5 and institutional connections that include ties to NATO, Yale, and the University of Alberta.6
Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) is a powerhouse, with advantages that put it right at the top of the booming functional mushrooms market that’s projected to reach +$34 billion by 2024.7
It has EVERYTHING it needs to cover all areas of medicine development, including synthesis, genetic research, import/export, delivery system development, and clinical trial execution, through to product commercialization and distribution.
Out of all of its advantages, perhaps its largest is its relationship with the API (Applied Pharmaceutical Innovations) at the University of Alberta, which holds a Schedule 1 license, which took 11 years to obtain, to research, develop, and produce a number of unique APIs (Active Pharmaceutical Ingredients) from their naturally-sourced cGMP psychedelic extracts from fungi.
The University of Alberta is recognized as being in the Top 15 for Global Research,8 and is Canada’s #1 AI hub9—as AI continues to play a huge role in these new discoveries.
Right now, researchers are paying $7,000 to $10,000 per gram10 for synthetic psilocybin—whereas MYCO can legally derive and produce the real organic version of the same fungal ingredients..
“Mydecine’s breakthrough to legally supply naturally-sourced psilocybin within our spore-to-sale™ process will be a major advancement for mental therapeutics, due to the fact that these unique psychedelic compounds are both safe and effective for afflictions, such as depression, anxiety, addiction, and PTSD.”
– Damon Michaels, COO and Co-Founder of Mydecine
Mydecine Has 3 Key Platforms For Success
- Mydecine Health Sciences deals with developing proprietary formulations of novel fungtional™ mushroom vitality products and psychedelic medicine to produce better options for people to live healthier lives.
- NeuroPharm™ is the clinical development arm, managing clinical trials through veteran and military channels, including the first-of-its-kind PTSD study, which has been featured in FORBES.
- Mindleap Health™ is an advanced digital telehealth platform helping people connect with mental health specialists who can empower them to thrive and develop habits for a healthy mind. Mindleap will also be a dedicated platform for the aftercare of psychedelic therapy.
On top of it all, the company boasts a state-of-the-art lab facility in Colorado,12 allowing MYCO to further capitalize on massive leverage to complete its ongoing mycology research.
Mydecine is also a 50% owner of Alternative Distribution Company (“ALT Distro.”), and already has established relationships with tens of thousands of retail outlets, including HEB, Costco, Whole Foods, Kroger, and more giving it an immediate head-start advantage when their newest products launch.
Top to bottom, Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) is a complete package run as a well-oiled machine by experts in business management, marketing, science, and mental health. It’s well-positioned to absolutely dominate the psychedelic medicine market and functional (better yet, “fungtional”) mushroom market.
Mental Health and Telehealth Stocks Outperforming the Street
Before we go into more detail about Mydecine’s business, let’s take a look at how the impact of this crisis has accelerated the growth of drug and telehealth companies.
The growth has been exponentially mind-boggling.
But, what we love about this company is it’s still in its early stages and one thing you must understand is that not all startups are created equal and we’ll outline the key reasons why Mydecine is a winner.
At $0.58 a share, it’s still priced low enough and at the stage where there is still a lot of blue sky potential if the company hits their goals.
Let’s take a look at Well Health. On January 1, 2019, the stock was $0.33 and it hit a high of $5.40 this year. That is a 1536% gain!
The gains for this industry have been eye-popping and the Canadian stock markets are seeing an unprecedented melt-up right now.
The coverage on psychedelics as medicine has been seen on 60 Minutes,13 Forbes,14 Fox Business,15 NPR,16 Today17 and investor interest is on the rise, with billionaire investors, celebrities, and high-profile execs endorsing the psychedelic medicine market either by joining strategic advisory boards or making sizable investments.18
In fact, there is so much interest in psychedelics medicine that some analysts see the industry bringing in $6.85 billion by 2027.19
Scott Adams, the creator of the Dilbert cartoon strip, pundit on YouTube and Periscope and resident of Northern California, claims that he took mushrooms once and it was the best day of his life and he no longer felt any limits to his life and career success.
Compass Pathways (backed by ATAI Life Sciences AG), received FDA breakthrough therapy designation on a treatment derived from… magic mushrooms.21
This active medical ingredient in these fungi is “psilocybin”.
In just the last two years, the Food and Drug Administration has twice22 granted “breakthrough therapy” status23 to psilocybin-assisted treatment for major depressive disorder and treatment-resistant depression.
To date, ATAI has successfully raised over US$100 million from major investors such as PayPal co-founder Peter Thiel—and right now they’re currently seeking a US$800 million valuation.24
Mydecine and Neuropharm™
Roughly 1 in 5 US adults experience a mental illness (47.6 million people), and a staggering 1 in 25 US adults experience a serious mental illness (11.4 million people), in a given year.25
And those stats were calculated before the lockdowns.
Where are these people going to get the help they need? From pills already available on the market?
Sadly, only between 43-64% of those suffering from mental illness have received treatment,26 and MORE THAN HALF of people who take antidepressants never get relief.27
Yet, they continue to be prescribed in greater and greater numbers, with 1 in 10 people over the age of 12 in the US now taking antidepressants, as usage between 1999-2014 increased 64%.28
Something’s gotta give. This is serious.
Finally we’re getting a novel approach to treating severe depression29 and PTSD30—psychedelics.
Neuropharm is currently performing the First-of-its-Kind Clinical Trial to study psychedelic (psilocybin) treatments for PTSD in Veterans.31
In collaboration with its strategic partners, Mydecine is deploying evidence-based medicine in the establishment of psychedelic-based therapies addressing the unmet needs of high-risk constituents.32
The NeuroPharm management team is composed of critically acclaimed scientists and upper echelon retired military personnel boasting extensive drug development experience and deep, embedded relationships within the Canadian and U.S. militaries.
Perhaps the largest advantage is in MYCO’s ability to derive a number of unique Active Pharmaceutical Ingredients (APIs) from their naturally-sourced cGMP psychedelic fungal extracts.
Mydecine will also be conducting R&D to produce novel proprietary formulations by synergizing psychedelic fungi compounds with other various API’s.
Scientists who want to study psychedelic mushrooms currently have to pay between $7,000 to $10,000 per gram for their materials!33
Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) through its partnership with the API at the University of Alberta can produce psilocybin at a fraction of the current market cost, producing the World’s First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution.34
This is a MAJOR gap, and ultimately perhaps the removal of the most significant barrier to research on the ingredient.
The Doctor Will See You Now
One of the saddest realities about mental health is the prohibitive nature of access to proper care.35
Mydecine and Mindleap Health™
Barriers to access include disparity in insurance coverage, rising costs, and now the added concern over social distancing limiting people’s willingness to receive in-person therapy.
This is where the innovation of Mindleap Health36 (“Mindleap”) a wholly owned subsidiary of Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA), stands out as a MAJOR tech injection into a sector that desperately needs it.
It’s one of the best use cases for the telemedicine industry. If a patient already suffers from mental health issues. It’s going to take a lot to have them drive to the doctor’s office, wait in the waiting room with other people with similar disorders and then have enough courage to speak to someone in person. Doesn’t it make sense to open up your app at home?
We feel that this is a game changer for this industry.
Mindleap is an AI-powered smart app platform that not only connects patients with their therapists, but also can significantly improve upon monitoring progress, provide follow-up treatment, and give patients other beneficial activities such as meditation, breathing work, and yoga instruction.
The Mindleap Platform37 will provide:
- Convenient and more affordable access to mental health services
- Psychedelic aftercare, addiction, and holistic wellness services
- On Demand access to mental health programs
- Automated appointment booking and international payments
- Secure and confidential video sessions
- Critical tools for improved outcomes and personalized care
- Easy to use software with fast learning curve for specialists
- Secured encrypted system that is HIPAA and GDPR compliant
- High engagement features and gamification that improve user experience
- Will NOT sell the user information to other companies
Its best outcomes perhaps come from its HIPAA-approved opt-in capabilities of habit tracking—ie. staring at your phone too long, negative messaging, abnormal sleeping patterns, long periods of inactivity and more.
Perhaps most importantly from a value-add standpoint is the useful data that Mydecine Innovations Group, Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) can collect from the platform’s connection to clinical environments across the globe from users that opt-in to sharing this data.
- Push for Alternative Therapies Prods Researchers Towards Psilocybin
- Mydecine Innovations Group Partners with Microdose Psychedelic Insights to Present a Free, Live Webinar Series on The Renaissance of Psychedelics
- Top Mushroom Penny Stocks To Watch For 2021
- Psychedelic Quick Hits: Havn Life, MindMed, Mydecine
- Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms
Mydecine’s Outstanding Team of Experts
Now, what will truly blow everyone away is the management team of experts that are backing this company. Take a look at these accomplishments:
- 100+ published peer-reviewed studies / papers
- World-class team coming from Pfizer, Novartis, Yale, Imperial College and Canadian, US and EU Militaries
- Proven drug development and approval experience
- 30+ years of combined psychedelic industry experience
- Accomplished entrepreneurs, multiple successful exits
- 7-Nobel Peace Prize Nominee
This is a STACKED team!
Investment highlights the market CAN’T IGNORE About Mydecine Innovations Group, Inc. (CSE:MYCO) (OTCQB:MYCOF) (FRA:0NFA):
Outstanding management, research teams, partners (military, scientists, researchers) and a chief marketing expert from Red Bull, as well as a distribution arm already serving 10s of thousands of retail outlets.
Controlled Drugs and Substances Schedule 1 Dealer’s Licenses from Health Canada that allow MYCO the ability to cultivate, import, export, extract, and commercialize psilocybin and other functional mushroom products.
Technology and Analytics from the Mindleap platform that’s connected to clinics across the globe, providing TONS of data that’s privacy protected, and can improve upon the AI capabilities of this state-of-the-art telemedicine service.
Equipped for industry leading research through 7,500 sq ft Colorado Lab and access to Top 15 Global Research through the University of Alberta.
Low cost cultivation that’s capable of deriving APIs from mushrooms at a cost of pennies per gram when scientists are currently paying $7,000-$10,000 per gram for synthetically derived ingredients, giving HUGE leverage to complete clinical studies.
First-of-its-Kind clinical trials (featured in Forbes), with a current pipeline of 8 studies lined up through 2021, through 7 different respected research institutions.
Distribution in place through Alternative Distribution which has access to 10s of thousands of retail outlets, including Costco, Whole Foods, and Kroger.